According to Fortune Business Insights, the global AI In Cancer Diagnostics Market size was valued at USD 1.06 billion in 2025 and is projected to grow from USD 1.28 billion in 2026 to USD 9.56 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 28.58% during the forecast period of 2026–2034. The market is experiencing substantial growth as healthcare providers increasingly adopt artificial intelligence (AI) to support early cancer detection, improve diagnostic accuracy, streamline clinical workflows, and analyze complex medical data. The growing prevalence of cancer and the increasing adoption of digital healthcare technologies are further supporting market expansion.

AI In Cancer Diagnostics Market Overview

Artificial intelligence is transforming cancer diagnostics by helping healthcare professionals analyze medical images, pathology slides, genomic information, and other diagnostic data. AI-powered systems use advanced algorithms, computer vision, machine learning, and deep learning to identify suspicious abnormalities, prioritize high-risk cases, and support clinical decision-making.

The growing demand for faster and more reliable cancer diagnosis is encouraging hospitals, diagnostic laboratories, and research institutions to integrate AI-enabled solutions into their workflows. These technologies can help reduce diagnostic workloads, improve consistency in medical image interpretation, and support the identification of cancer at earlier stages.

AI is also increasingly being applied to digital pathology, liquid biopsy analysis, biomarker identification, and cancer screening. As healthcare systems invest in connected diagnostic infrastructure, the adoption of AI-based cancer diagnostic platforms is expected to increase across developed and emerging markets.

Request a Free Sample: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/ai-in-cancer-diagnostics-market-115859

Key Market Trends Driving Growth

Increasing Adoption of AI in Early Cancer Detection

Early cancer detection is a major priority for healthcare systems worldwide. AI-powered diagnostic tools can help identify suspicious patterns in mammograms, CT scans, MRI scans, and pathology images. These technologies assist healthcare professionals in prioritizing cases that may require further examination and support more efficient screening programs.

As cancer screening volumes increase, healthcare providers are investing in AI solutions to improve diagnostic workflows and manage growing patient demand.

Growing Use of Digital Pathology and Biomarker Analysis

Digital pathology is becoming an important application area for AI in cancer diagnostics. AI algorithms can analyze digitized tissue slides, identify potentially abnormal cellular patterns, and support quantitative biomarker assessment.

The increasing adoption of biomarker testing in oncology is creating demand for tools that help standardize scoring and improve reporting efficiency. These capabilities are particularly valuable for laboratories handling large volumes of cancer samples.

Rising Demand for Personalized Cancer Diagnosis

Personalized medicine is increasing the importance of understanding the molecular and genetic characteristics of individual tumors. AI technologies can help researchers and clinicians interpret complex genomic datasets, identify potential biomarkers, and support the classification of cancer subtypes.

The integration of AI with genomic testing and liquid biopsy technologies is expected to create additional opportunities for more targeted diagnostic approaches and treatment planning.

Expansion of Cloud-Based Diagnostic Platforms

Cloud-based AI platforms enable healthcare organizations to deploy diagnostic applications across multiple facilities, manage software updates, and support collaboration between specialists. These solutions can also help diagnostic networks standardize workflows and scale their operations.

The growing digitization of healthcare systems and the demand for interoperable diagnostic technologies are expected to support the adoption of cloud-enabled cancer diagnostic solutions.

Key Factors Driving the AI In Cancer Diagnostics Market

Rising Global Cancer Burden

The increasing number of cancer cases is placing pressure on healthcare systems to improve diagnostic capacity and reduce delays. Hospitals and laboratories are seeking technologies that can help manage growing workloads without requiring a proportional increase in specialist resources.

AI-enabled tools can support case prioritization, image interpretation, and diagnostic consistency, making them increasingly attractive for cancer screening and diagnosis.

Technological Advancements in Artificial Intelligence

Continuous advancements in machine learning, deep learning, computer vision, and natural language processing are expanding the capabilities of AI-powered diagnostic systems. These technologies can process large datasets and recognize patterns that may be difficult to identify consistently through conventional workflows alone.

Ongoing innovation is expected to support the development of more specialized AI applications for different cancer types and diagnostic procedures.

Increasing Investments and Strategic Collaborations

Healthcare technology companies, diagnostic solution providers, research institutions, and medical device manufacturers are investing in AI-enabled cancer diagnosis. Strategic partnerships and product launches are helping organizations integrate AI into imaging systems, digital pathology platforms, and clinical workflows.

These collaborations are expected to support commercialization, expand the availability of AI-powered diagnostic solutions, and strengthen competition across the market.

AI In Cancer Diagnostics Market Segmentation

The market is segmented by component, technology, modality, application, deployment, cancer type, end user, and region.

By Component

The market is divided into software and services. The software segment accounted for the largest market share in 2025, supported by demand for AI engines and platforms that integrate with imaging systems, pathology viewers, and diagnostic workflows. Software solutions can be deployed across multiple users and facilities, making them an important component of enterprise-wide AI adoption.

The services segment supports implementation, integration, training, maintenance, and technical assistance. It is expected to expand as healthcare organizations adopt increasingly complex AI diagnostic systems.

By Technology

The market is categorized into computer vision, machine learning and deep learning, natural language processing, and others.

Computer vision accounted for the largest market share in 2025 because of its extensive use in medical imaging and digital pathology. It enables AI systems to analyze scans and pathology slides, identify suspicious regions, and quantify relevant findings.

Natural language processing is also gaining traction as healthcare organizations seek to extract useful information from clinical notes, pathology reports, and other unstructured medical records. The segment is projected to grow at a CAGR of 32.25% during the forecast period.

By Modality

The market is divided into liquid biopsies, imaging diagnostics, digital pathology AI, genomics and biomarker discovery, and others.

Liquid biopsies dominated the market in 2025, supported by growing demand for minimally invasive testing and AI-assisted interpretation of complex molecular data. These technologies can help identify actionable genetic alterations and support cancer monitoring and treatment selection.

Digital pathology AI is another rapidly expanding area, with the segment projected to grow at a CAGR of 32.08% during the study period.

By Application

The market includes screening support, triage and prioritization, staging support, quantification and biomarker scoring, clinical decision support, and others.

Screening support accounted for the largest market share, reflecting the need to manage increasing diagnostic volumes and improve the efficiency of cancer screening programs. AI tools can assist healthcare professionals by flagging suspicious findings and supporting consistent evaluation.

The triage and prioritization segment is projected to grow at a CAGR of 31.39% during the forecast period as healthcare providers increasingly use AI to prioritize high-risk cases and improve diagnostic turnaround times.

By Deployment

The market is categorized into cloud-based, on-premises, and hybrid deployments.

Cloud-based deployment held the largest market share in 2025 because it enables scalable implementation, centralized software management, and deployment across multiple healthcare facilities. These solutions can help organizations manage growing diagnostic workloads and maintain consistent AI workflows.

Hybrid deployment is also expected to gain traction, particularly among organizations seeking to combine cloud-based scalability with local data processing and infrastructure control.

By Cancer Type

The market covers breast cancer, lung cancer, colorectal cancer, prostate cancer, brain and nervous system cancers, and others.

Breast cancer accounted for a significant market share in 2025, supported by the adoption of AI-assisted mammography and breast imaging solutions. These technologies can help identify suspicious abnormalities and prioritize cases requiring additional assessment.

The lung cancer segment is projected to grow at a CAGR of 31.24% during the forecast period, driven by increasing demand for AI-assisted analysis of lung imaging and the need to improve diagnostic efficiency.

By End User

The market is segmented into hospitals and ambulatory surgical centers (ASCs), diagnostic laboratories, research and academic institutes, and others.

Hospitals and ASCs dominated the market because they coordinate imaging, pathology, and other diagnostic services across patient care pathways. These organizations are investing in AI platforms to improve operational efficiency, support clinical workflows, and manage growing diagnostic workloads.

Diagnostic laboratories are also increasing their adoption of AI-powered technologies. The segment is projected to grow at a CAGR of 30.80% during the forecast period as laboratories expand digital pathology and automated diagnostic capabilities.

Regional Analysis of the AI In Cancer Diagnostics Market

North America

North America dominated the global AI In Cancer Diagnostics Market with a 38.67% share in 2025, reaching a market value of approximately USD 0.49 billion. The region benefits from established healthcare infrastructure, strong investment in medical technology, and the commercialization of AI-enabled diagnostic solutions.

The United States is a major contributor to regional growth, supported by the adoption of advanced imaging technologies, digital pathology platforms, and AI-based screening solutions. Increasing efforts to improve diagnostic efficiency and manage cancer screening workloads are expected to support further market development.

Europe

Europe represents a significant market for AI-powered cancer diagnostic technologies. The regional market is expected to reach approximately USD 0.33 billion in 2026, supported by investments in diagnostic IT infrastructure, digital healthcare initiatives, and standardized screening programs.

Countries such as Germany and the U.K. are contributing to market development through the adoption of advanced diagnostic technologies and the expansion of AI applications in healthcare.

Asia Pacific

Asia Pacific is projected to reach approximately USD 0.32 billion in 2026. Rising cancer incidence, expanding healthcare infrastructure, and increasing investment in digital diagnostic technologies are supporting regional growth.

China, Japan, and India represent important markets as healthcare providers seek to improve diagnostic capacity and expand access to advanced medical technologies. Growing interest in digital pathology, medical imaging AI, and personalized medicine is expected to create additional opportunities.

Latin America and the Middle East & Africa

Latin America and the Middle East & Africa are expected to experience market growth as private diagnostic networks expand and healthcare organizations invest in modern imaging and laboratory infrastructure.

Increasing awareness of early cancer detection and the need to improve diagnostic efficiency are creating opportunities for AI solution providers. However, adoption may vary depending on healthcare funding, digital infrastructure, regulatory requirements, and the availability of trained professionals.

Competitive Landscape of the AI In Cancer Diagnostics Market

The global market is characterized by competition among AI developers, medical technology companies, and digital pathology solution providers. Market participants are focusing on product innovation, strategic partnerships, regulatory clearances, and the integration of AI into existing diagnostic workflows.

Key companies operating in the market include:

  • Aidoc Medical, Ltd.
  • Lunit Inc.
  • Paige.AI, Inc.
  • Ibex Medical Analytics Ltd.
  • iCAD, Inc.
  • ScreenPoint Medical B.V.
  • Proscia Inc.
  • SOPHiA GENETICS SA
  • Tempus AI, Inc.
  • Medtronic plc.

These companies are working to strengthen their market positions through advanced diagnostic software, AI-enabled imaging applications, digital pathology solutions, and collaborations with healthcare providers.

Recent Industry Developments

  • March 2026: Lord's Mark Industries Limited collaborated with the Centre for Materials for Electronic Technology (C-MET) under a technology transfer agreement to manufacture an AI-powered, radiation-free breast screening wearable device designed to support early cancer detection.
  • March 2026: Perimeter Medical Imaging AI, Inc. received U.S. FDA premarket approval for Claire, an AI-enabled imaging device designed to assist with intraoperative breast cancer margin assessment.
  • August 2025: PathAI collaborated with Moffitt Cancer Center to deploy its AISight Dx digital pathology platform across the center's pathology programs, supporting cancer diagnostics and research.
  • February 2025: Aiforia Technologies Plc obtained In Vitro Diagnostic Regulation certification and launched three CE-IVD-marked AI models for breast and prostate cancer diagnostics in Europe.
  • October 2024: DeepHealth acquired Kheiron Medical Technologies Limited, expanding its portfolio of AI-powered mammography and breast cancer screening solutions.

Read Report Insights: https://www.fortunebusinessinsights.com/ai-in-cancer-diagnostics-market-115859

Future Outlook of the AI In Cancer Diagnostics Market

The AI In Cancer Diagnostics Market is expected to experience strong growth through 2034 as healthcare providers increasingly integrate artificial intelligence into cancer screening, imaging, pathology, and molecular diagnostics. Rising cancer incidence, technological advancements, and the growing need for faster diagnostic workflows are likely to remain important growth drivers.

Digital pathology, liquid biopsy analysis, AI-assisted imaging, and biomarker assessment are expected to create new opportunities for technology developers and healthcare organizations. However, regulatory complexity, reimbursement uncertainty, data privacy requirements, and the need for clinical validation may influence the pace of adoption.

Companies that demonstrate clinical reliability, effective integration with existing healthcare systems, and measurable improvements in diagnostic workflows are likely to be well positioned to benefit from the market's long-term expansion.

Frequently Asked Questions (FAQs)

1. What is the global AI In Cancer Diagnostics Market size?

The global AI In Cancer Diagnostics Market was valued at USD 1.06 billion in 2025 and is projected to grow from USD 1.28 billion in 2026 to USD 9.56 billion by 2034.

2. What is the expected CAGR of the AI In Cancer Diagnostics Market?

The market is projected to grow at a CAGR of 28.58% during the forecast period from 2026 to 2034.

3. What are the key factors driving the AI In Cancer Diagnostics Market?

Major growth drivers include rising cancer incidence, increasing demand for early detection, advancements in artificial intelligence, expanding digital pathology adoption, and growing investments in AI-enabled diagnostic solutions.

4. Which segment dominates the AI In Cancer Diagnostics Market?

By component, software accounted for the largest market share in 2025. By technology, computer vision held the leading position, while liquid biopsies dominated by modality and screening support led by application.

5. Which region dominates the AI In Cancer Diagnostics Market?

North America dominated the global market in 2025, accounting for 38.67% of the market share, supported by advanced healthcare infrastructure and growing adoption of AI-powered diagnostic technologies.

Uncover Japan’s Market Trends - Explore the Latest - AI In Cancer Diagnostics Market- Insights